Gilead Sciences Inc
* Gilead receives approval in Canada for Epclusa (sofosbuvir/velpatasvir), the first once-daily pan-genotypic (genotypes 1-6) single tablet regimen for the treatment of chronic Hepatitis C Source text for Eikon: Further company coverage
No comments:
Post a Comment